{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:42:36Z","timestamp":1786653756368,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Schizophrenia can coexist with obsessive-compulsive symptoms (OCSs). This study aimed to assess the efficacy of adding Fluoxetine-gold standard for the treatment of obsessive-compulsive disorder to the treatment regimen of patients with schizophrenia and OCS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients diagnosed with schizophrenia (according to ICD-11) and OCS (assessed via the Y-BOCS Checklist) were randomized to either the Add-on Fluoxetine (received Fluoxetine in addition to their ongoing antipsychotic treatment) or the Antipsychotic only (continued with standard therapy) using a computer-generated random number table and assessed using PANSS, CGI-global impression, and SOFAS. Baseline assessments were conducted to evaluate sociodemographic and clinical factors and the severity of OCS. Both groups were monitored over 8 weeks for changes in psychotic and obsessive-compulsive symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy patients of schizophrenia with OCS were recruited, 35 in each group. Both groups demonstrated significant improvement over 8 weeks in psychotic and obsessive-compulsive symptoms. The Add-on Fluoxetine exhibited earlier and more pronounced symptom improvements. A significant difference was found in the YBOCS compulsion score, with a median score of 8 (7\u201310) in the Add-on Fluoxetine and 11 (9.5\u201312) in the Antipsychotic only (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value of 0.003). Add-on Fluoxetine had a lower median score on CGI global improvement, 3 (3\u20133), and CGI efficacy index, 10 (10\u201310), than the Antipsychotic only, 4 (3\u20134) and 14 (10\u201314), respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.001). Fluoxetine was well tolerated, with minimal reported side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The findings suggest that adjunctive Fluoxetine treatment led to early resolution of psychopathology and improved overall outcomes in schizophrenia with co-occurring OCS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/indianjpsychiatry_757_24","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:01:50Z","timestamp":1752595310000},"page":"666-674","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Randomized controlled trial of add-on Fluoxetine versus usual antipsychotic treatment in obsessive compulsive symptoms in schizophrenia"],"prefix":"10.4103","volume":"67","author":[{"given":"Manya","family":"Agarwal","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivangi","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Sidana","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India"},{"name":"Department of Psychiatry, NEIGRIHMS, Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/neu.2018.27","article-title":"Obsessive-compulsive Symptoms in schizophrenia: A review","volume":"31","author":"Grover","year":"2018","journal-title":"Acta Neuropsychiatr"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"100539","DOI":"10.1016\/j.jocrd.2020.100539","article-title":"Comorbidity of obsessive-compulsive and psychotic experiences: A systematic review and meta-analysis","volume":"26","author":"Mawn","year":"2020","journal-title":"J Obsessive Compuls Relat Disord"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.psychres.2017.01.067","article-title":"Obsessive compulsive symptoms\/disorder in patients with schizophrenia: Prevalence, relationship with other symptom dimensions and impact on functioning","volume":"250","author":"Grover","year":"2017","journal-title":"Psychiatry Res"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004714-199506000-00009","article-title":"Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine","volume":"15","author":"Berman","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-199903000-00006","article-title":"Fluvoxamine treatment of obsessive compulsive symptoms in schizophrenic patients: An add-on open study","volume":"14","author":"Poyurovsky","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.4088\/JCP.v69n1202","article-title":"Aripiprazole in Schizophrenia patients with comorbid obsessive-compulsive symptoms","volume":"69","author":"Glick","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/0269881108099215","article-title":"Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms","volume":"24","author":"Poyurovsky","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/YIC.0b013e32835bd24e","article-title":"Escitalopram in the treatment of patients with schizophrenia and obsessive\u2013compulsive disorder","volume":"28","author":"Stryjer","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.euroneuro.2014.06.014","article-title":"Treatment with Ziprasidone for schizophrenia patients with OCD","volume":"24","author":"Juven-Wetzler","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjment-2023-300951","article-title":"Influence of study characteristics, methodological rigour and publication bias on efficacy of pharmacotherapy in obsessive-compulsive disorder: A systematic review and meta-analysis of randomised, placebo-controlled trials","volume":"27","author":"Cohen","year":"2024","journal-title":"BMJ Ment Health"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/wps.20189","article-title":"The development of the ICD-11 clinical descriptions and diagnostic guidelines for mental and behavioural disorders","volume":"14","author":"First","year":"2015","journal-title":"World Psychiatry"},{"key":"R14-20260421","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The Yale-Brown obsessive compulsive scale. II. Validity","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"R15-20260421","article-title":"The Mental Healthcare Act. 2017","journal-title":"Ministry of Law and Justice"},{"key":"R16-20260421","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R17-20260421","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"R18-20260421","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"R19-20260421","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.149.9.1148","article-title":"Revising axis V for DSM-IV: a review of measures of social functioning","volume":"149","author":"Goldman","year":"1992","journal-title":"Am J Psychiatry"},{"key":"R20-20260421","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/0269881107087976","article-title":"Glasgow antipsychotic side effect scale","volume":"22","author":"Waddell","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R21-20260421","first-page":"22","article-title":"SSRI Antidepressant Medications: Adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R22-20260421","first-page":"324","article-title":"Obsessive-compulsive symptoms in chronic schizophrenia: A new idea or an old belief?","volume":"39","author":"Jaydeokar","year":"1997","journal-title":"Indian J Psychiatry"},{"key":"R23-20260421","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ajp.2018.11.016","article-title":"Prevalence and clinical correlations of obsessive-compulsive symptoms in schizophrenia","volume":"39","author":"Singh","year":"2019","journal-title":"Asian J Psychiatr"},{"key":"R24-20260421","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2022.12.013","article-title":"Relationship between obsessive compulsive symptomatology and severity of psychotic symptoms in schizophrenia: Meta-analysis and meta-regression analysis","volume":"251","author":"Cunill","year":"2023","journal-title":"Schizophr Res"},{"key":"R25-20260421","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.comppsych.2014.09.015","article-title":"Prevalence and clinical correlates of obsessive\u2013compulsive disorder in schizophrenia","volume":"56","author":"Devi","year":"2015","journal-title":"Compr Psychiatry"},{"key":"R27-20260421","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/ajp.143.4.437","article-title":"The prognostic significance of obsessive-compulsive symptoms in schizophrenia","volume":"143","author":"Fenton","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R28-20260421","first-page":"291","article-title":"Treatment of obsessive compulsive symptoms in schizophrenia with fluoxetine","volume":"42","author":"Agarwal","year":"2000","journal-title":"Indian J Psychiatry"},{"key":"R29-20260421","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00005053-200001000-00010","article-title":"Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms","volume":"188","author":"Arango","year":"2000","journal-title":"J Nerv Mental Dis"},{"key":"R31-20260421","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00004714-200008000-00004","article-title":"Obsessive and compulsive symptoms in schizophrenia: A randomized controlled trial with fluvoxamine and neuroleptics","volume":"20","author":"Reznik","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R32-20260421","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/14656566.2016.1186646","article-title":"May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia?","volume":"17","author":"Buoli","year":"2016","journal-title":"Expert Opin Pharmacother"}],"container-title":["Indian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/indianjpsychiatry_757_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:50Z","timestamp":1786650110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/indianjpsychiatry_757_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/indianjpsychiatry_757_24","relation":{},"ISSN":["0019-5545","1998-3794"],"issn-type":[{"value":"0019-5545","type":"print"},{"value":"1998-3794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-09-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}